tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Enanta Pharmaceuticals Inc

ENTA
Add to Watchlist
12.600USD
-0.400-3.08%
Close 07-31 16:00（ET）Quotes delayed by 15 min
366.39MMarket Cap
LossP/E TTM

Enanta Pharmaceuticals Inc

12.600
-0.400-3.08%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

ENTA Financials

See Enanta Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Enanta Pharmaceuticals Inc Earnings Date

Latest Release
Aug 10, 2026
EPS / Forecast
--/-0.51
Revenue / Forecast
--/16.80M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
65.32M
-3.42%
EPS(YoY)
-3.84
30.03%
Analyst Rating
BUY
2026/08/02
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Financial Indicators
EPS
57.49%-0.45
60.43%-0.42
35.68%-0.87
20.17%-0.85
27.96%-1.06
33.75%-1.05
-1.90%-1.36
42.34%-1.07
17.78%-1.47
-13.77%-1.58
---1.33
---1.86
---1.79
---1.39
----
----
----
----
----
----
Revenue
14.96%17.16M
9.76%18.61M
3.55%15.13M
1.91%18.31M
-12.48%14.93M
-5.80%16.96M
-22.84%14.61M
-4.88%17.97M
-4.16%17.05M
-23.67%18.00M
-6.82%18.93M
-3.01%18.89M
-4.92%17.80M
-14.70%23.59M
-13.82%20.32M
-9.92%19.48M
-7.03%18.72M
-12.90%27.65M
-0.24%23.57M
15.93%21.62M
Net Profit
42.19%-13.09M
46.44%-11.94M
35.12%-18.70M
19.43%-18.25M
27.32%-22.64M
33.28%-22.29M
-2.55%-28.82M
42.00%-22.66M
17.26%-31.16M
-15.25%-33.41M
-6.68%-28.11M
-23.23%-39.06M
-12.10%-37.66M
3.75%-28.99M
-7.11%-26.35M
-31.95%-31.70M
-52.38%-33.59M
-261.61%-30.11M
16.16%-24.60M
-68.41%-24.02M
Net Margin
49.71%-76.29%
51.21%-64.13%
37.34%-123.64%
20.94%-99.68%
16.96%-151.71%
29.17%-131.43%
-32.91%-197.32%
39.03%-126.08%
13.67%-182.70%
-50.99%-185.56%
---148.46%
---206.78%
---211.62%
---122.90%
----
----
----
----
----
----
Gross Margin
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
--100.00%
--100.00%
--100.00%
--100.00%
----
----
----
----
----
----
Debt to assets ratio
9789.32%41.33%
10568.06%41.31%
14127.10%50.99%
25.69%0.45%
21.47%0.42%
16.60%0.39%
16.43%0.36%
24.16%0.36%
-21.06%0.34%
-18.90%0.33%
--0.31%
--0.29%
--0.44%
--0.41%
----
----
----
----
----
----
Income Statement
Revenue
14.96%17.16M
9.76%18.61M
3.55%15.13M
1.91%18.31M
-12.48%14.93M
-5.80%16.96M
-22.84%14.61M
-4.88%17.97M
-4.16%17.05M
-23.67%18.00M
-6.82%18.93M
-3.01%18.89M
-4.92%17.80M
-14.70%23.59M
-13.82%20.32M
-9.92%19.48M
-7.03%18.72M
-12.90%27.65M
-0.24%23.57M
15.93%21.62M
Operating profit
51.68%-11.85M
52.20%-11.25M
38.41%-18.39M
21.88%-18.89M
25.14%-24.53M
32.51%-23.54M
3.79%-29.85M
34.12%-24.18M
16.95%-32.77M
-16.24%-34.89M
-14.72%-31.03M
-12.82%-36.71M
-16.56%-39.45M
1.30%-30.01M
19.80%-27.05M
3.86%-32.54M
-13.96%-33.85M
-147.25%-30.41M
-70.48%-33.73M
-48.11%-33.85M
Net Profit
42.19%-13.09M
46.44%-11.94M
35.12%-18.70M
19.43%-18.25M
27.32%-22.64M
33.28%-22.29M
-2.55%-28.82M
42.00%-22.66M
17.26%-31.16M
-15.25%-33.41M
-6.68%-28.11M
-23.23%-39.06M
-12.10%-37.66M
3.75%-28.99M
-7.11%-26.35M
-31.95%-31.70M
-52.38%-33.59M
-261.61%-30.11M
16.16%-24.60M
-68.41%-24.02M
Balance Sheet
Current assets
-26.54%178.41M
-25.90%198.68M
-31.85%204.34M
-22.29%222.71M
-30.81%242.86M
-31.30%268.14M
-29.08%299.85M
-36.10%286.58M
29.47%351.03M
37.57%390.30M
35.63%422.79M
43.26%448.46M
-20.69%271.14M
-13.23%283.70M
-2.29%311.71M
-2.53%313.04M
-20.16%341.87M
-26.68%326.96M
-26.97%319.02M
-22.31%321.15M
Total current liabilities
1.08%46.44M
-8.81%44.73M
-15.61%48.55M
-26.04%44.55M
-15.86%45.95M
-21.40%49.05M
-8.36%57.53M
-11.66%60.24M
69.77%54.61M
171.32%62.41M
110.50%62.79M
196.02%68.19M
4.65%32.17M
-39.30%23.00M
-17.54%29.83M
-19.53%23.04M
15.48%30.74M
64.42%37.89M
49.74%36.17M
19.70%28.62M
Total assets
-2.57%314.70M
-5.49%329.50M
-25.47%280.73M
-24.52%301.03M
-21.90%322.99M
-18.64%348.64M
-18.52%376.65M
-19.46%398.82M
26.69%413.56M
23.30%428.50M
23.14%462.27M
28.54%495.17M
-19.76%326.44M
-21.12%347.53M
-14.44%375.41M
-14.48%385.21M
-13.03%406.82M
-8.40%440.59M
-9.74%438.79M
-11.97%450.44M
Total liabilities
-13.66%198.12M
-14.32%202.91M
-12.84%216.01M
-11.97%221.75M
-7.27%229.46M
0.09%236.83M
0.94%247.84M
-2.11%251.91M
333.58%247.44M
406.70%236.62M
354.06%245.54M
445.34%257.35M
18.32%57.07M
-16.92%46.70M
37.38%54.08M
44.82%47.19M
51.99%48.23M
93.71%56.21M
28.84%39.36M
4.62%32.59M
Total equity
24.64%116.59M
13.21%126.59M
-49.76%64.72M
-46.76%79.28M
-43.69%93.54M
-41.73%111.82M
-40.57%128.81M
-37.38%148.91M
-38.33%166.11M
-36.22%191.88M
-32.55%216.74M
-29.64%237.82M
-24.88%269.38M
-21.74%300.84M
-19.55%321.33M
-19.10%338.02M
-17.76%358.58M
-14.96%384.38M
-12.33%399.43M
-13.05%417.85M
Cash Flow Statement
Net operating income
46.95%-7.16M
30.37%-11.70M
37.61%-6.49M
218.48%17.51M
52.84%-13.49M
32.76%-16.80M
51.86%-10.40M
54.01%-14.78M
-107.51%-28.60M
29.89%-24.99M
-39.06%-21.60M
-8.53%-32.13M
47.74%-13.78M
-168.56%-35.64M
26.10%-15.53M
-0.33%-29.60M
-476.00%-26.38M
10.87%-13.27M
-35.96%-21.02M
-557.44%-29.51M
Net investment
373.33%11.94M
-168.64%-47.30M
-87.96%2.30M
-317.38%-26.48M
-107.45%-4.37M
625.30%68.90M
61.14%19.07M
95.65%-6.34M
25.36%58.62M
-139.07%-13.12M
-58.07%11.84M
-998.57%-145.75M
233.40%46.77M
-26.22%33.57M
-61.16%28.23M
137.11%16.22M
-237.70%-35.05M
360.83%45.50M
2802.68%72.68M
-263.21%-43.70M
Net financing
-5.92%-7.29M
1386.32%64.14M
-15.33%-8.32M
3.35%-6.42M
-7.37%-6.89M
32.16%-4.99M
-31269.57%-7.21M
-103.33%-6.65M
-216.43%-6.41M
-2541.86%-7.35M
-100.78%-23.00K
4751.33%199.88M
-160.49%-2.03M
-96.88%301.00K
210.71%2.93M
500.58%4.12M
190.89%3.35M
3121.40%9.63M
304.72%943.00K
-78.74%686.00K

FAQs

What is the total revenue of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its total revenue reached 65.32M, with a year-on-year change of 67.64M.

What are the current assets of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its current assets were 204.34M, with a year-on-year change of -31.85.

What are the total assets of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its total assets of Enanta Pharmaceuticals Inc were 280.73M, with a year-on-year change of -25.47.

What are the total liabilities of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Enanta Pharmaceuticals Inc were 216.01M, with a year-on-year change of -12.84.

What is the total equity of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its total equity of Enanta Pharmaceuticals Inc was 64.72M, with a year-on-year change of -49.76.

What is the net operating income of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Enanta Pharmaceuticals Inc was -85.35M, with a year-on-year change of 29.86.

What is the net investment of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its net investment of Enanta Pharmaceuticals Inc was 40.35M, with a year-on-year change of -30.72.

What is the net financing of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its net financing of Enanta Pharmaceuticals Inc was -26.62M, with a year-on-year change of 3.65.

What is the Earnings Per Share (EPS) of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -3.84, with a year-on-year change of 30.03.

What is the net income of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its net income was -81.89M, with a year-on-year change of 29.43.

What is the net margin of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its net profit margin was -125.36, with a year-on-year change of 26.94.

What is the debt-to-asset ratio of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its debt-to-asset ratio was 50.99, with a year-on-year change of 14127.10.

What is the Return on Equity (ROE) of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its Return on Equity (ROE) was -84.63, with a year-on-year change of -26.00.

What is the Return on Assets (ROA) of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was -24.91, with a year-on-year change of 9.95.

What is the operating profit of Enanta Pharmaceuticals Inc?

According to Enanta Pharmaceuticals Inc's FY2025 earnings report, its operating profit was -85.35M, with a year-on-year change of 29.86.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy